Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen L Reeves

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Diabetes, Obesity & Metabolism|February 17, 2017
Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytesZiad H Al-Oanzi, Sophia Fountana, Tabassum Moonira, et al.
Journal of Hepatology|May 2, 2016
Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?Laura F Ogle, James G Orr, Catherine E Willoughby, et al.
Cancer Research|June 3, 2004
Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1Sharon Benzeno, Goutham Narla, Jorge Allina, et al.
Gastroenterology|June 3, 2008
The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver diseaseLuca Miele, Gary Beale, Gillian Patman, et al.
Hepatic Medicine : Evidence and Research|May 24, 2019
Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom populationMunirah Alsaleh, Thomas A Barbera, Helen L Reeves, et al.
BMC Cancer|August 7, 2009
A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver diseaseJoe Gray, Dipankar Chattopadhyay, Gary S Beale, et al.
Hepatology (Baltimore, Md.)|October 16, 2004
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinomaSigal Kremer-Tal, Helen L Reeves, Goutham Narla, et al.
Chemical Science|June 30, 2017
Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatasesTristan Reuillon, Sari F Alhasan, Gary S Beale, et al.
British Journal of Cancer|August 26, 2016
Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinomaSari F Alhasan, Beate Haugk, Laura F Ogle, et al.
Liver Cancer|March 6, 2023
Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver DiseaseHaonan Lu, Jacob George, Mohammed Eslam, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Diabetes, Obesity & Metabolism|February 17, 2017
Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytesZiad H Al-Oanzi, Sophia Fountana, Tabassum Moonira, et al.
Journal of Hepatology|May 2, 2016
Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?Laura F Ogle, James G Orr, Catherine E Willoughby, et al.
Cancer Research|June 3, 2004
Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1Sharon Benzeno, Goutham Narla, Jorge Allina, et al.
Gastroenterology|June 3, 2008
The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver diseaseLuca Miele, Gary Beale, Gillian Patman, et al.
Hepatic Medicine : Evidence and Research|May 24, 2019
Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom populationMunirah Alsaleh, Thomas A Barbera, Helen L Reeves, et al.
BMC Cancer|August 7, 2009
A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver diseaseJoe Gray, Dipankar Chattopadhyay, Gary S Beale, et al.
Hepatology (Baltimore, Md.)|October 16, 2004
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinomaSigal Kremer-Tal, Helen L Reeves, Goutham Narla, et al.
Chemical Science|June 30, 2017
Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatasesTristan Reuillon, Sari F Alhasan, Gary S Beale, et al.
British Journal of Cancer|August 26, 2016
Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinomaSari F Alhasan, Beate Haugk, Laura F Ogle, et al.
Liver Cancer|March 6, 2023
Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver DiseaseHaonan Lu, Jacob George, Mohammed Eslam, et al.
Pageof 7